(R)-2-HG - a-KG-dependent dioxygenases inhibitor. CAS# 103404-90-6 60225 Smiles: C(C1C=CC=CC=1)N1C(=NC2=CC=CC=C12)C1C=CC(=CC=1)OC[C@H](C1CCNCC1)N1C(=NC2=CC=CC=C12)C1C=CC=CC=1

Smiles: C(C1C=CC=CC=1)N1C(=NC2=CC=CC=C12)C1C=CC(=CC=1)OC[C@H](C1CCNCC1)N1C(=NC2=CC=CC=C12)C1C=CC=CC=1

5-trimethoxyphenyl)amino)pyrimidin-4-yl)oxy)-N-methylbenzamide

NVP-BGT226

BUQ57 was dosed to mice bearing human lung cancer cell line H2122 xenografts by intraperitoneal injection at 50 mg/Kg once per day

(R)-2-HG - a-KG-dependent dioxygenases inhibitor. CAS# 103404-90-6 60225 Smiles: C(C1C=CC=CC=1)N1C(=NC2=CC=CC=C12)C1C=CC(=CC=1)OC[C@H](C1CCNCC1)N1C(=NC2=CC=CC=C12)C1C=CC=CC=1Mutations, CAS No. 103404 90 6, in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several human cancers, such as leukemia and glioma, and result in overproduction of the (R) enantiomer of 2 hydroxyglutarate [(R) 2 HG]. Elucidation of the role of IDH mutations and (R) 2 HG in leukemogenesis has been hampered by a lack of appropriate cell based models. It has been recently reported that a canonical IDH1 mutant, IDH1